Under the agreement, Par Sterile, a subsidiary of Endo International, has begun production of the NVX-CoV2373 final drug candidate, with initial batches to be used in Novavax's phase III clinical trial in the U.S. Par Sterile will also fill-finish vaccine intended for commercial distribution in the U.S.

NVX-CoV2373 is currently in multiple phase II clinical trials to evaluate safety and immunogenicity. Interim data is expected before the end of 2020. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including $388 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Financial and other terms of the agreement were not disclosed.

Novavax begins phase II trial of COVID-19 vaccine
Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373,...

Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...

AGC expands partnership with Novavax in U.S.
AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate...

Novavax licenses COVID-19 vaccine to Takeda in Japan
Novavax and Takeda Pharmaceutical have formed a partnership for the development, manufacturing, and commercialization in Japan of NVX-CoV2373, Novavax's...